154 related articles for article (PubMed ID: 36369706)
21. TERT promoter mutations in telomere biology.
Heidenreich B; Kumar R
Mutat Res Rev Mutat Res; 2017; 771():15-31. PubMed ID: 28342451
[TBL] [Abstract][Full Text] [Related]
22. Frequent somatic TERT promoter mutations and CTNNB1 mutations in hepatocellular carcinoma.
Lee SE; Chang SH; Kim WY; Lim SD; Kim WS; Hwang TS; Han HS
Oncotarget; 2016 Oct; 7(43):69267-69275. PubMed ID: 27661004
[TBL] [Abstract][Full Text] [Related]
23. TERT promoter mutations in primary liver tumors.
Nault JC; Zucman-Rossi J
Clin Res Hepatol Gastroenterol; 2016 Feb; 40(1):9-14. PubMed ID: 26336998
[TBL] [Abstract][Full Text] [Related]
24. Frequency of TERT promoter mutations in primary tumors of the liver.
Quaas A; Oldopp T; Tharun L; Klingenfeld C; Krech T; Sauter G; Grob TJ
Virchows Arch; 2014 Dec; 465(6):673-7. PubMed ID: 25267585
[TBL] [Abstract][Full Text] [Related]
25. Telomere length variation in tumor cells and cancer-associated fibroblasts: potential biomarker for hepatocellular carcinoma.
Ma LJ; Wang XY; Duan M; Liu LZ; Shi JY; Dong LQ; Yang LX; Wang ZC; Ding ZB; Ke AW; Cao Y; Zhang XM; Zhou J; Fan J; Gao Q
J Pathol; 2017 Dec; 243(4):407-417. PubMed ID: 28833123
[TBL] [Abstract][Full Text] [Related]
26. Telomerase reverse transcriptase (TERT) promoter mutation correlated with intratumoral heterogeneity in hepatocellular carcinoma.
Kwa WT; Effendi K; Yamazaki K; Kubota N; Hatano M; Ueno A; Masugi Y; Sakamoto M
Pathol Int; 2020 Sep; 70(9):624-632. PubMed ID: 32559017
[TBL] [Abstract][Full Text] [Related]
27. Cause-specific telomere factors deregulation in hepatocellular carcinoma.
El Idrissi M; Hervieu V; Merle P; Mortreux F; Wattel E
J Exp Clin Cancer Res; 2013 Sep; 32(1):64. PubMed ID: 24020493
[TBL] [Abstract][Full Text] [Related]
28. Expression of Cellular and Extracellular
Manganelli M; Grossi I; Corsi J; D'Agostino VG; Jurikova K; Cusanelli E; Molfino S; Portolani N; Salvi A; De Petro G
Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682861
[TBL] [Abstract][Full Text] [Related]
29. Telomerase activity, telomere length and human telomerase reverse transcriptase expression in hepatocellular carcinoma is independent of hepatitis virus status.
Saini N; Srinivasan R; Chawla Y; Sharma S; Chakraborti A; Rajwanshi A
Liver Int; 2009 Sep; 29(8):1162-70. PubMed ID: 19627485
[TBL] [Abstract][Full Text] [Related]
30. Androgen Receptor Enhances Hepatic Telomerase Reverse Transcriptase Gene Transcription After Hepatitis B Virus Integration or Point Mutation in Promoter Region.
Li CL; Li CY; Lin YY; Ho MC; Chen DS; Chen PJ; Yeh SH
Hepatology; 2019 Feb; 69(2):498-512. PubMed ID: 30070724
[TBL] [Abstract][Full Text] [Related]
31. Distinct Patterns of HBV Integration and
Jang JW; Kim HS; Kim JS; Lee SK; Han JW; Sung PS; Bae SH; Choi JY; Yoon SK; Han DJ; Kim TM; Roberts LR
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34209079
[TBL] [Abstract][Full Text] [Related]
32. Noncoding telomeric repeat-containing RNA inhibits the progression of hepatocellular carcinoma by regulating telomerase-mediated telomere length.
Cao H; Zhai Y; Ji X; Wang Y; Zhao J; Xing J; An J; Ren T
Cancer Sci; 2020 Aug; 111(8):2789-2802. PubMed ID: 32357278
[TBL] [Abstract][Full Text] [Related]
33. Prediction of the prognosis of advanced hepatocellular carcinoma by TERT promoter mutations in circulating tumor DNA.
Hirai M; Kinugasa H; Nouso K; Yamamoto S; Terasawa H; Onishi Y; Oyama A; Adachi T; Wada N; Sakata M; Yasunaka T; Onishi H; Shiraha H; Takaki A; Okada H
J Gastroenterol Hepatol; 2021 Apr; 36(4):1118-1125. PubMed ID: 32830343
[TBL] [Abstract][Full Text] [Related]
34. Telomerase reverse transcriptase suppression inhibits cell proliferation and promotes cell apoptosis in hepatocellular cancer.
Shen Y; Xi F; Li H; Luo Y; Chen C; Wang L
IUBMB Life; 2018 Jul; 70(7):642-648. PubMed ID: 29707886
[TBL] [Abstract][Full Text] [Related]
35. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.
Nault JC; Mallet M; Pilati C; Calderaro J; Bioulac-Sage P; Laurent C; Laurent A; Cherqui D; Balabaud C; Zucman-Rossi J
Nat Commun; 2013; 4():2218. PubMed ID: 23887712
[TBL] [Abstract][Full Text] [Related]
36. HCV core inhibits hepatocellular carcinoma cell replicative senescence through downregulating microRNA-138 expression.
Shiu TY; Shih YL; Feng AC; Lin HH; Huang SM; Huang TY; Hsieh CB; Chang WK; Hsieh TY
J Mol Med (Berl); 2017 Jun; 95(6):629-639. PubMed ID: 28258280
[TBL] [Abstract][Full Text] [Related]
37. Genetic diagnostic test of hepatocellular carcinoma by telomerase catalytic subunit mRNA.
Wada E; Hisatomi H; Moritoyo T; Kanamaru T; Hikiji K
Oncol Rep; 1998; 5(6):1407-12. PubMed ID: 9769378
[TBL] [Abstract][Full Text] [Related]
38. [Studies on telomerase reverse transcriptase components and liver cancer].
Cai JJ; Guo XL
Zhonghua Gan Zang Bing Za Zhi; 2016 Jul; 24(7):555-560. PubMed ID: 27784441
[TBL] [Abstract][Full Text] [Related]
39. The CCCTC-binding factor (CTCF)-forkhead box protein M1 axis regulates tumour growth and metastasis in hepatocellular carcinoma.
Zhang B; Zhang Y; Zou X; Chan AW; Zhang R; Lee TK; Liu H; Lau EY; Ho NP; Lai PB; Cheung YS; To KF; Wong HK; Choy KW; Keng VW; Chow LM; Chan KK; Cheng AS; Ko BC
J Pathol; 2017 Dec; 243(4):418-430. PubMed ID: 28862757
[TBL] [Abstract][Full Text] [Related]
40. Telomerase reverse transcriptase moonlights: Therapeutic targets beyond telomerase.
Maida Y; Masutomi K
Cancer Sci; 2015 Nov; 106(11):1486-92. PubMed ID: 26331588
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
